Thalassemia
Conditions
Brief summary
This is a single centre、single arm、open-label study，to investigate the safety and efficacy of the gene correction of HBB in patient-specific iHSCs using CRISPR/Cas9.
Detailed description
The purpose of this study is to evaluate the efficacy and safety of transplantation iHSCs intervent subjests with β-thalassemia mutations.
Interventions
BIOLOGICALiHSCs treatment group
iHSCs intravenous injection
Sponsors
Allife Medical Science and Technology Co., Ltd.
Study design
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Subjects ≥ 2 and ≤ 60 years of age 2. Subjects was confirmed the transfusion-dependent β-thalassemia 3. Adequate organ function, as defined by: Serum creatinine ≤ 1.5 mg/dl ； Serum ALT/AST）≤2.5×ULN；ALB≥25g/L； Serum total bilirubin \< 1.5x ULN Left ventricular ejection fraction≥50% 4. Chest X-ray and ecg test results were normal, no serious cardiopulmonary diseases 5. Subjects survival was expected≥6 months 6. Adult patients were willing to use reliable contraceptives (such as condoms) and not to donate sperm throughout the study period and within three months of discharge 7. Subjects and the guardians able to undergo post-physical therapy/rehabilitation
Exclusion criteria
1. Subjects allergic to macromolecular biological agents such as antibodies or cytokines 2. Subjects receipt of any investigational clinical trials within 3 months. 3. Subjects previous treatment with any hematopoietic stem cell transplantation or other organ transplantation 4. Uncontrolled bleeding symptoms 5. Severe cardiovascular disease is known, including any of the following: Myocardial infarction or thrombosis has occurred in the past six months Subjects with unstable angina pectoris Subjects with Class III/IV cardiovascular disability according to the New York Heart Association Classification 6. Subjects have one kinds of tumors within 5 years 7. Active hepatitis B (HBV DNA\>1000copy/mL), hepatitis C or HIV infection. 8. Subjects have an infectious diseases that cannot be controlled within 4 weeks 9. subjects have severe central nervous system disease or epilepsy 10. Subjects are Suffering from mental illness; Patients with alcohol dependence, drug abuse, drug addiction, and medical, psychological or social conditions that may interfere with research or have an impact on the evaluation of research results 11. Women in pregnancy (positive urine/blood pregnancy test) or lactation 12. Subjects who have other conditions that were not appropriate for the group determined by the researchers.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Occurrence of treatment related adverse events as assessed by CTCAE v4.0 | 1 year | Defined as \>= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment |
Outcome results
None listed